En Es
Categories

Industry News

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

By Labmedica International staff writers
09 Nov 2022

Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining panels, tissue staining, and imaging and analysis services.


Cell IDx's UltraPlex technology allows simultaneous detection of multiple biomarkers in many immunoassays through fluorescent and chromogenic multiplex immunohistochemistry (IHC) staining technology, and automated chromogenic detection of multiple markers on Leica Biosystems' BOND RX fully automated research stainer. Together, UltraPlex and BOND RX with high throughput imaging allows researchers to detect three or more markers chromogenically on a single slide using a straightforward pathology workflow. In 2021, Leica Biosystems and Cell IDx had announced a partnership to combine the benefits of UltraPlex and BOND RX; now, Leica Biosystems has acquired Cell IDx, advancing this partnership and adding both scale-up capability and Medical and Scientific Affairs support for Cell IDx customers.


"We are thrilled to welcome Cell IDx to the Leica Biosystems team," said Gustavo Perez-Fernandez, President of Leica Biosystems. "This acquisition will expand our capabilities in the translational research segment and help researchers to accelerate their journey, transforming scientific exploration into translational outcomes."


"The ability to differentiate multiple targets in brightfield has been a long-standing unmet need in clinical pathology. Multiplex chromogenic IHC allows the pathologist to, for example, detect targets inside and outside the tumor. This data on a single tissue section has the potential to inform real time therapy decisions and produce a more focused patient centric approach," said David Schwartz, co-founder and former CEO of Cell IDx. "Getting this technology into the hands of researchers will advance the science of cancer diagnostics and improve lives. We are delighted to be a part of this mission."


"The Cell IDx technology promotes the translation of complex multiplex IHC signatures into manageable three and four biomarker panels that can be automated on Leica Biosystems' BOND RX platform for high quality, reproducible staining," said Robert Monroe, Chief Medical Officer at Leica Biosystems. "We see the pairing of UltraPlex and BOND automation as a platform for the creation of next generation tissue-based diagnostics for better prediction of therapeutic response and tumor behavior."


Related Links:
Leica Biosystems
Cell IDx, Inc. 



E-mail Print
FaceBook Twitter Google+ Linked in

LEICA

Leica Biosystems develops and supplies cancer diagnostics devices and solutions in the areas of histology, digital pathology, and clinical micsorocopy, surgery and radiology. Its workflow solutions and automation enable clinicians to efficiently provide patients a diagnosis within 24-hours from biopsy.
More info

Additional news

25 Jan 2023
Global Diagnostic Imaging Services Market Driven by Rising Prevalence of Chronic Diseases
The global diagnostic imaging services market was valued at USD 40.80 billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period 2022-2030 to reach USD 67.94 billion in 2030, driven by the rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry.
Read More
25 Jan 2023
Global Endoscopy Equipment Market Driven by Growing Hospital Investment in Advanced Instruments
The global endoscopy equipment market is projected to register a CAGR of 7% from USD 28.9 billion in 2022 to USD 40.6 billion by 2027, driven by increasing demand for endoscopy to diagnose and treat target diseases, rising investments, funds, and grants by governments and other organizations across the world, and growing focus by hospitals on investing in technologically-advanced endoscopy instruments and expanding endoscopy units.
Read More
25 Jan 2023
Point-of-Care Glucose Testing Market to Reach Almost USD 6 Billion by 2032
The global point-of-care (POC) glucose testing market is projected to register a CAGR of 4.3% during the forecast period from 2022 to 2032 to reach USD 5.8 billion by 2032, driven by a rise in the geriatric population, speed & precision of POC screening, increased adoption of electronic medical information, and the higher risk of COVID-19-related mortality associated with diabetes.
Read More
24 Jan 2023
Carolina Liquid Chemistries and Diazyme Enter Into Partnership
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.
Read More
23 Jan 2023
Mindray Defibrillators Amongst the World’s First to Receive MDR Clearance
Mindray has received the CE marking for its defibrillation product family under the European Union's newest Medical Device Regulation (MDR). With the new rule tightening the controls for defibrillation devices, Mindray has become among the first manufacturers in the world to earn MDR accreditation for product quality and effectiveness.
Read More
23 Jan 2023
Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland
Siemens Healthineers has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders.
Read More
20 Jan 2023
Global Intensive Care Unit (ICU) Equipment Market Driven By Increasing Neurological Diseases
The global intensive care unit (ICU) equipment market was valued at USD 6.6 billion in 2021 and is estimated to register a CAGR of 3.9% from 2022 to 2031 to reach USD 9.6 billion by 2031, driven primarily by a rise in the prevalence of neurological diseases.
Read More
20 Jan 2023
Bayer Acquires Imaging AI Platform Provider in the UK
Bayer (Leverkusen, Germany) has acquired Blackford Analysis Ltd. (Edinburgh, UK), a global strategic imaging AI platform and solutions provider. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance the company’s position in digital medical imaging.
Read More
16 Jan 2023
Medlab Middle East Sees 100% Increase in Exhibitor Numbers
Medlab Middle East, the MENA region’s largest medical laboratory exhibition and congress, has sold out its exhibitor space ahead of the show, which returns to the Dubai World Trade Centre from February 6 to 9, 2023.
Read More
Copyright © 2000-2023 TradeMed.com. All rights reserved. | Terms And Conditions